Cancer immunotherapy in progress-an overview of the past 130 years
Since the first approval of an immune-checkpoint inhibitor, we have witnessed the clinical success of cancer immunotherapy. Adoptive T-cell therapy with chimeric antigen-receptor T (CAR-T) cells has shown remarkable efficacy in hematological malignancies. Concurrently with these successes, the cance...
Gespeichert in:
| Veröffentlicht in: | International immunology 2025-01 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | International immunology |
| container_volume | |
| creator | Ikeda, Hiroaki |
| description | Since the first approval of an immune-checkpoint inhibitor, we have witnessed the clinical success of cancer immunotherapy. Adoptive T-cell therapy with chimeric antigen-receptor T (CAR-T) cells has shown remarkable efficacy in hematological malignancies. Concurrently with these successes, the cancer immunoediting concept that refined the cancer immunosurveillance concept underpinned the scientific mechanism and reason for past failures, as well as recent breakthroughs in cancer immunotherapy. Now, we face the next step of issues to be solved in this field, such as tumor heterogeneity, the tumor microenvironment, the metabolism of tumors and the immune system, and personalized approaches for patients, aiming to expand the population benefitted by the therapies. |
| doi_str_mv | 10.1093/intimm/dxaf002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3153923638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3153923638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c958-f4c9188ff75ad993e253c8c9c6f6f66cf770725ad2633058cf19d2b3f0afa9083</originalsourceid><addsrcrecordid>eNpNkE1PwzAMhiMEYmNw5Yhy5NLNidcmOcLElzSJy-5RliZQ1C-SdrB_T6cOhHywJT9-ZT2EXDOYM1C4KOquqKpF_m08AD8hU7bMIOEoxOm_eUIuYvwAAOQKz8kElVAcpJyS-5WprQt0COnrpnt3wbR7WtS0Dc1bcDEmpqbNzoVd4b5o4-mA0NbEjjIEuncmxEty5k0Z3dWxz8jm8WGzek7Wr08vq7t1YlUqE7-0iknpvUhNrhQ6nqKVVtnMD5VZLwQIPux4hgiptJ6pnG_Rg_FGgcQZuR1jh88-exc7XRXRurI0tWv6qJGlqDhmeEDnI2pDE2NwXrehqEzYawb6oE2P2vRR23Bwc8zut5XL__BfT_gDTlpqjw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3153923638</pqid></control><display><type>article</type><title>Cancer immunotherapy in progress-an overview of the past 130 years</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Ikeda, Hiroaki</creator><creatorcontrib>Ikeda, Hiroaki</creatorcontrib><description>Since the first approval of an immune-checkpoint inhibitor, we have witnessed the clinical success of cancer immunotherapy. Adoptive T-cell therapy with chimeric antigen-receptor T (CAR-T) cells has shown remarkable efficacy in hematological malignancies. Concurrently with these successes, the cancer immunoediting concept that refined the cancer immunosurveillance concept underpinned the scientific mechanism and reason for past failures, as well as recent breakthroughs in cancer immunotherapy. Now, we face the next step of issues to be solved in this field, such as tumor heterogeneity, the tumor microenvironment, the metabolism of tumors and the immune system, and personalized approaches for patients, aiming to expand the population benefitted by the therapies.</description><identifier>ISSN: 1460-2377</identifier><identifier>EISSN: 1460-2377</identifier><identifier>DOI: 10.1093/intimm/dxaf002</identifier><identifier>PMID: 39792088</identifier><language>eng</language><publisher>England</publisher><ispartof>International immunology, 2025-01</ispartof><rights>The Author(s) 2025. Published by Oxford University Press on behalf of The Japanese Society for Immunology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c958-f4c9188ff75ad993e253c8c9c6f6f66cf770725ad2633058cf19d2b3f0afa9083</cites><orcidid>0000-0002-8012-4796</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39792088$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ikeda, Hiroaki</creatorcontrib><title>Cancer immunotherapy in progress-an overview of the past 130 years</title><title>International immunology</title><addtitle>Int Immunol</addtitle><description>Since the first approval of an immune-checkpoint inhibitor, we have witnessed the clinical success of cancer immunotherapy. Adoptive T-cell therapy with chimeric antigen-receptor T (CAR-T) cells has shown remarkable efficacy in hematological malignancies. Concurrently with these successes, the cancer immunoediting concept that refined the cancer immunosurveillance concept underpinned the scientific mechanism and reason for past failures, as well as recent breakthroughs in cancer immunotherapy. Now, we face the next step of issues to be solved in this field, such as tumor heterogeneity, the tumor microenvironment, the metabolism of tumors and the immune system, and personalized approaches for patients, aiming to expand the population benefitted by the therapies.</description><issn>1460-2377</issn><issn>1460-2377</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNpNkE1PwzAMhiMEYmNw5Yhy5NLNidcmOcLElzSJy-5RliZQ1C-SdrB_T6cOhHywJT9-ZT2EXDOYM1C4KOquqKpF_m08AD8hU7bMIOEoxOm_eUIuYvwAAOQKz8kElVAcpJyS-5WprQt0COnrpnt3wbR7WtS0Dc1bcDEmpqbNzoVd4b5o4-mA0NbEjjIEuncmxEty5k0Z3dWxz8jm8WGzek7Wr08vq7t1YlUqE7-0iknpvUhNrhQ6nqKVVtnMD5VZLwQIPux4hgiptJ6pnG_Rg_FGgcQZuR1jh88-exc7XRXRurI0tWv6qJGlqDhmeEDnI2pDE2NwXrehqEzYawb6oE2P2vRR23Bwc8zut5XL__BfT_gDTlpqjw</recordid><startdate>20250110</startdate><enddate>20250110</enddate><creator>Ikeda, Hiroaki</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8012-4796</orcidid></search><sort><creationdate>20250110</creationdate><title>Cancer immunotherapy in progress-an overview of the past 130 years</title><author>Ikeda, Hiroaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c958-f4c9188ff75ad993e253c8c9c6f6f66cf770725ad2633058cf19d2b3f0afa9083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ikeda, Hiroaki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ikeda, Hiroaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer immunotherapy in progress-an overview of the past 130 years</atitle><jtitle>International immunology</jtitle><addtitle>Int Immunol</addtitle><date>2025-01-10</date><risdate>2025</risdate><issn>1460-2377</issn><eissn>1460-2377</eissn><abstract>Since the first approval of an immune-checkpoint inhibitor, we have witnessed the clinical success of cancer immunotherapy. Adoptive T-cell therapy with chimeric antigen-receptor T (CAR-T) cells has shown remarkable efficacy in hematological malignancies. Concurrently with these successes, the cancer immunoediting concept that refined the cancer immunosurveillance concept underpinned the scientific mechanism and reason for past failures, as well as recent breakthroughs in cancer immunotherapy. Now, we face the next step of issues to be solved in this field, such as tumor heterogeneity, the tumor microenvironment, the metabolism of tumors and the immune system, and personalized approaches for patients, aiming to expand the population benefitted by the therapies.</abstract><cop>England</cop><pmid>39792088</pmid><doi>10.1093/intimm/dxaf002</doi><orcidid>https://orcid.org/0000-0002-8012-4796</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1460-2377 |
| ispartof | International immunology, 2025-01 |
| issn | 1460-2377 1460-2377 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3153923638 |
| source | Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| title | Cancer immunotherapy in progress-an overview of the past 130 years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T13%3A30%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20immunotherapy%20in%20progress-an%20overview%20of%20the%20past%20130%20years&rft.jtitle=International%20immunology&rft.au=Ikeda,%20Hiroaki&rft.date=2025-01-10&rft.issn=1460-2377&rft.eissn=1460-2377&rft_id=info:doi/10.1093/intimm/dxaf002&rft_dat=%3Cproquest_cross%3E3153923638%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3153923638&rft_id=info:pmid/39792088&rfr_iscdi=true |